Equivocal, explicit and emergent actions of PKC isoforms in cancer.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
accepted:
02
10
2020
pubmed:
13
11
2020
medline:
2
2
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
The maturing mutational landscape of cancer genomes, the development and application of clinical interventions and evolving insights into tumour-associated functions reveal unexpected features of the protein kinase C (PKC) family of serine/threonine protein kinases. These advances include recent work showing gain or loss-of-function mutations relating to driver or bystander roles, how conformational constraints and plasticity impact this class of proteins and how emergent cancer-associated properties may offer opportunities for intervention. The profound impact of the tumour microenvironment, reflected in the efficacy of immune checkpoint interventions, further prompts to incorporate PKC family actions and interventions in this ecosystem, informed by insights into the control of stromal and immune cell functions. Drugging PKC isoforms has offered much promise, but when and how is not obvious.
Identifiants
pubmed: 33177705
doi: 10.1038/s41568-020-00310-4
pii: 10.1038/s41568-020-00310-4
doi:
Substances chimiques
Isoenzymes
0
Protein Kinase C
EC 2.7.11.13
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-63Subventions
Organisme : Cancer Research UK
ID : FC001130
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001130
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001130
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Références
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
pubmed: 12471243
Mellor, H. & Parker, P. J. The extended protein kinase C superfamily. Biochem. J. 332, 281–292 (1998).
pubmed: 9601053
pmcid: 1219479
Levin, D. E., Fields, F. O., Kunisawa, R., Bishop, J. M. & Thorner, J. A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle. Cell 62, 213–224 (1990).
pubmed: 2196995
Suh, P. G. et al. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep. 41, 415–434 (2008).
pubmed: 18593525
Bunney, T. D. & Katan, M. PLC regulation: emerging pictures for molecular mechanisms. Trends Biochem. Sci. 36, 88–96 (2011).
pubmed: 20870410
Haga, R. B. & Ridley, A. J. Rho GTPases: regulation and roles in cancer cell biology. Small GTPases 7, 207–221 (2016).
pubmed: 27628050
pmcid: 5129894
Castagna, M. et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 257, 7847–7851 (1982). This paper is the first to define PKC as a target for tumour promoters.
pubmed: 7085651
Gallegos, L. L. & Newton, A. C. Spatiotemporal dynamics of lipid signaling: protein kinase C as a paradigm. IUBMB Life 60, 782–789 (2008).
pubmed: 18720411
pmcid: 2718795
Tobias, I. S. & Newton, A. C. Protein scaffolds control localized protein kinase Cζ activity. J. Biol. Chem. 291, 13809–13822 (2016).
pubmed: 27143478
pmcid: 4919463
Hong, Y. aPKC: the kinase that phosphorylates cell polarity. F1000Res 7, 903 (2018).
Amano, M. et al. Identification of a putative target for Rho as the serine–threonine kinase protein kinase N. Science 271, 648–650 (1996).
pubmed: 8571127
Bauer, A. F. et al. Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2–PRK2 interaction mediated by its N-terminal domain. J. Biol. Chem. 287, 20590–20602 (2012).
pubmed: 22511787
pmcid: 3370243
Jaken, S. & Parker, P. J. Protein kinase C binding partners. Bioessays 22, 245–254 (2000).
pubmed: 10684584
Schechtman, D. & Mochly-Rosen, D. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 20, 6339–6347 (2001).
pubmed: 11607837
Saurin, A. T. et al. The regulated assembly of a PKCε complex controls the completion of cytokinesis. Nat. Cell Biol. 10, 891–901 (2008).
pubmed: 18604201
Schonwasser, D. C., Marais, R. M., Marshall, C. J. & Parker, P. J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell Biol. 18, 790–798 (1998).
pubmed: 9447975
pmcid: 108790
Le Good, J. A. et al. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281, 2042–2045 (1998).
pubmed: 9748166
Chou, M. M. et al. Regulation of protein kinase Cζ by PI3-kinase and PDK-1. Curr. Biol. 8, 1069–1077 (1998).
pubmed: 9768361
Dutil, E. M., Toker, A. & Newton, A. C. Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr. Biol. 8, 1366–1375 (1998).
pubmed: 9889098
Cameron, A. J., Linch, M. D., Saurin, A. T., Escribano, C. & Parker, P. J. mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem. J. 439, 287–297 (2011).
pubmed: 21806543
Newton, A. C. Protein kinase C as a tumor suppressor. Semin. Cancer Biol. 48, 18–26 (2018).
pubmed: 28476658
Cameron, A. J., Escribano, C., Saurin, A. T., Kostelecky, B. & Parker, P. J. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat. Struct. Mol. Biol. 16, 624–630 (2009). This paper demonstrates that in cells the occupation of the nucleotide binding pocket of PKC with nucleotides or inhibitors has a profound impact on its priming phosphorylation state.
pubmed: 19465915
Gould, C. M. et al. Active site inhibitors protect protein kinase C from dephosphorylation and stabilize its mature form. J. Biol. Chem. 286, 28922–28930 (2011).
pubmed: 21715334
pmcid: 3190699
Srivastava, J., Goris, J., Dilworth, S. M. & Parker, P. J. Dephosphorylation of PKCδ by protein phosphatase 2Ac and its inhibition by nucleotides. FEBS Lett. 516, 265–269 (2002).
pubmed: 11959144
Torbett, N. E., Casamassima, A. & Parker, P. J. Hyperosmotic-induced protein kinase N 1 activation in a vesicular compartment is dependent upon Rac1 and 3-phosphoinositide-dependent kinase 1. J. Biol. Chem. 278, 32344–32351 (2003).
pubmed: 12783890
Newton, A. C. Protein kinase C: poised to signal. Am. J. Physiol. Endocrinol. Metab. 298, E395–E402 (2010).
pubmed: 19934406
Balendran, A., Hare, G. R., Kieloch, A., Williams, M. R. & Alessi, D. R. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484, 217–223 (2000).
pubmed: 11078882
Cameron, A. J. et al. Protein kinases, from B to C. Biochem. Soc. Trans. 35, 1013–1017 (2007).
pubmed: 17956266
Nishikawa, K., Toker, A., Johannes, F. J., Songyang, Z. & Cantley, L. C. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J. Biol. Chem. 272, 952–960 (1997).
pubmed: 8995387
Betson, M. & Settleman, J. A rho-binding protein kinase C-like activity is required for the function of protein kinase N in Drosophila development. Genetics 176, 2201–2212 (2007).
pubmed: 17507675
pmcid: 1950625
Lachmann, S. et al. Regulatory domain selectivity in the cell-type specific PKN-dependence of cell migration. PLoS ONE 6, e21732 (2011).
pubmed: 21754995
pmcid: 3130767
Carracedo, S., Sacher, F., Brandes, G., Braun, U. & Leitges, M. Redundant role of protein kinase Cδ and epsilon during mouse embryonic development. PLoS ONE 9, e103686 (2014).
pubmed: 25084151
pmcid: 4118884
Linch, M. et al. A cancer-associated mutation in atypical protein kinase Cι occurs in a substrate-specific recruitment motif. Sci. Signal. 6, ra82 (2013).
pubmed: 24045153
Pears, C. J., Kour, G., House, C., Kemp, B. E. & Parker, P. J. Mutagenesis of the pseudosubstrate site of protein kinase C leads to activation. Eur. J. Biochem. 194, 89–94 (1990).
pubmed: 2253627
Antal, C. E., Callender, J. A., Kornev, A. P., Taylor, S. S. & Newton, A. C. Intramolecular C2 domain-mediated autoinhibition of protein kinase C βII. Cell Rep. 12, 1252–1260 (2015).
pubmed: 26279568
pmcid: 4551583
Stabel, S., Rodriguez-Pena, A., Young, S., Rozengurt, E. & Parker, P. J. Quantitation of protein kinase C by immunoblot—expression in different cell lines and response to phorbol esters. J. Cell Physiol. 130, 111–117 (1987).
pubmed: 3543027
Lee, H. W., Smith, L., Pettit, G. R. & Smith, J. B. Bryostatin 1 and phorbol ester down-modulate protein kinase C-α and -ε via the ubiquitin/proteasome pathway in human fibroblasts. Mol. Pharmacol. 51, 439–447 (1997).
pubmed: 9058599
Lee, H. W., Smith, L., Pettit, G. R., Vinitsky, A. & Smith, J. B. Ubiquitination of protein kinase C-α and degradation by the proteasome. J. Biol. Chem. 271, 20973–20976 (1996).
pubmed: 8702857
Lu, Z. et al. Activation of protein kinase C triggers its ubiquitination and degradation. Mol. Cell Biol. 18, 839–845 (1998).
pubmed: 9447980
pmcid: 108795
Hansra, G. et al. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes. Biochem. J. 342, 337–344 (1999).
pubmed: 10455020
pmcid: 1220470
Prevostel, C., Alice, V., Joubert, D. & Parker, P. J. Protein kinase Cα actively downregulates through caveolae-dependent traffic to an endosomal compartment. J. Cell Sci. 113, 2575–2584 (2000).
pubmed: 10862715
Leontieva, O. V. & Black, J. D. Identification of two distinct pathways of protein kinase Cα down-regulation in intestinal epithelial cells. J. Biol. Chem. 279, 5788–5801 (2004).
pubmed: 14638691
Lum, M. A., Pundt, K. E., Paluch, B. E., Black, A. R. & Black, J. D. Agonist-induced down-regulation of endogenous protein kinase Cα through an endolysosomal mechanism. J. Biol. Chem. 288, 13093–13109 (2013).
pubmed: 23508961
pmcid: 3642351
Melnikov, S. & Sagi-Eisenberg, R. Down-regulating protein kinase Cα: functional cooperation between the proteasome and the endocytic system. Cell Signal. 21, 1607–1619 (2009).
pubmed: 19586612
Chen, D. et al. Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin ligase. J. Biol. Chem. 282, 33776–33787 (2007).
pubmed: 17893151
Min, X., Zhang, X., Sun, N., Acharya, S. & Kim, K. M. Mdm2-mediated ubiquitination of PKCβII in the nucleus mediates clathrin-mediated endocytic activity. Biochem. Pharmacol. 170, 113675 (2019).
pubmed: 31634457
Nakamura, M., Tokunaga, F., Sakata, S. & Iwai, K. Mutual regulation of conventional protein kinase C and a ubiquitin ligase complex. Biochem. Biophys. Res. Commun. 351, 340–347 (2006).
pubmed: 17069764
Baffi, T. R., Van, A. N., Zhao, W., Mills, G. B. & Newton, A. C. Protein kinase C quality control by phosphatase PHLPP1 unveils loss-of-function mechanism in cancer. Mol. Cell 74, 378–392.e5 (2019).
pubmed: 30904392
pmcid: 6504549
Abrahamsen, H. et al. Peptidyl-prolyl isomerase Pin1 controls down-regulation of conventional protein kinase C isozymes. J. Biol. Chem. 287, 13262–13278 (2012).
pubmed: 22318721
pmcid: 3339987
Perander, M., Bjorkoy, G. & Johansen, T. Nuclear import and export signals enable rapid nucleocytoplasmic shuttling of the atypical protein kinase Cλ. J. Biol. Chem. 276, 13015–13024 (2001).
pubmed: 11115515
Ivaska, J., Bosca, L. & Parker, P. J. PKCε is a permissive link in integrin-dependent IFN-γ signalling that facilitates JAK phosphorylation of STAT1. Nat. Cell Biol. 5, 363–369 (2003).
pubmed: 12640464
Pelech, S. L., Meier, K. E. & Krebs, E. G. Rapid microassay for protein kinase C translocation in Swiss 3T3 cells. Biochemistry 25, 8348–8353 (1986).
pubmed: 3828283
Sakai, N. et al. Direct visualization of the translocation of the γ-subspecies of protein kinase C in living cells using fusion proteins with green fluorescent protein. J. Cell Biol. 139, 1465–1476 (1997).
pubmed: 9396752
pmcid: 2132627
Gao, X. et al. Single cell analysis of PKC activation during proliferation and apoptosis induced by laser irradiation. J. Cell Physiol. 206, 441–448 (2006).
pubmed: 16155941
Flint, A. J., Paladini, R. D. & Koshland, D. E. Jr. Autophosphorylation of protein kinase C at three separated regions of its primary sequence. Science 249, 408–411 (1990).
pubmed: 2377895
Ng, T. et al. Imaging protein kinase Cα activation in cells. Science 283, 2085–2089 (1999).
pubmed: 10092232
Durgan, J. et al. The identification and characterization of novel PKCε phosphorylation sites provide evidence for functional cross-talk within the PKC superfamily. Biochem. J. 411, 319–331 (2008).
pubmed: 18237277
Durgan, J., Michael, N., Totty, N. & Parker, P. J. Novel phosphorylation site markers of protein kinase Cδ activation. FEBS Lett. 581, 3377–3381 (2007).
pubmed: 17603046
Rodriguez, J. et al. aPKC cycles between functionally distinct PAR protein assemblies to drive cell polarity. Dev. Cell 42, 400–415.e9 (2017).
pubmed: 28781174
pmcid: 5563072
Wodarz, A. & Näthke, I. Cell polarity in development and cancer. Nat. Cell Biol. 9, 1016–1024 (2007).
pubmed: 17762893
Linch, M. et al. Regulation of polarized morphogenesis by protein kinase Cι in oncogenic epithelial spheroids. Carcinogenesis 35, 396–406 (2014).
pubmed: 24072773
Slaga, T. J. Overview of tumor promotion in animals. Env. Health Perspect. 50, 3–14 (1983).
Hecker, E. Three stage carcinogenesis in mouse skin — recent results and present status of an advanced model system of chemical carcinogenesis. Toxicol. Pathol. 15, 245–258 (1987).
pubmed: 3112923
Balmain, A. Transforming ras oncogenes and multistage carcinogenesis. Br. J. Cancer 51, 1–7 (1985).
pubmed: 3881118
pmcid: 1976808
Fujiki, H., Sueoka, E. & Suganuma, M. Tumor promoters: from chemicals to inflammatory proteins. J. Cancer Res. Clin. Oncol. 139, 1603–1614 (2013).
pubmed: 23756937
Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308, 693–698 (1984).
pubmed: 6232463
Ono, Y. et al. Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc. Natl Acad. Sci. USA 86, 4868–4871 (1989). This paper is the first demonstration that the cysteine-rich C1 domains are bound by phorbol esters, impacting our definition of this entire class of responsive proteins.
pubmed: 2500657
Fujiki, H. et al. Activation of calcium-activated, phospholipid-dependent protein kinase (protein kinase C) by new classes of tumor promoters: teleocidin and debromoaplysiatoxin. Biochem. Biophys. Res. Commun. 120, 339–343 (1984).
pubmed: 6233970
Miyake, R. et al. Activation of protein kinase C by non-phorbol tumor promoter, mezerein. Biochem. Biophys. Res. Commun. 121, 649–656 (1984).
pubmed: 6233978
Arcoleo, J. P. & Weinstein, I. B. Activation of protein kinase C by tumor promoting phorbol esters, teleocidin and aplysiatoxin in the absence of added calcium. Carcinogenesis 6, 213–217 (1985).
pubmed: 3156004
Thastrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R. & Dawson, A. P. Thapsigargin, a tumor promoter, discharges intracellular Ca
pubmed: 2138778
Haystead, T. A. et al. Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 337, 78–81 (1989).
pubmed: 2562908
Manzow, S., Richter, K. H., Stempka, L., Fürstenberger, G. & Marks, F. Evidence against a role of general protein kinase C downregulation in skin tumor promotion. Int. J. Cancer 85, 503–507 (2000).
pubmed: 10699922
Arnott, C. H. et al. Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway. Oncogene 21, 4728–4738 (2002).
pubmed: 12101411
Kazanietz, M. G. Novel “nonkinase” phorbol ester receptors: the C1 domain connection. Mol. Pharmacol. 61, 759–767 (2002).
pubmed: 11901214
Soloff, R. S., Katayama, C., Lin, M. Y., Feramisco, J. R. & Hedrick, S. M. Targeted deletion of protein kinase Cλ reveals a distribution of functions between the two atypical protein kinase C isoforms. J. Immunol. 173, 3250–3260 (2004).
pubmed: 15322187
Quetier, I. et al. Knockout of the PKN family of rho effector kinases reveals a non-redundant role for PKN2 in developmental mesoderm expansion. Cell Rep. 14, 440–448 (2016).
pubmed: 26774483
pmcid: 4733087
Oster, H. & Leitges, M. Protein kinase Cα but not PKCζ suppresses intestinal tumor formation in Apc
pubmed: 16849539
Cataisson, C. et al. Activation of cutaneous protein kinase Cα induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways. J. Immunol. 171, 2703–2713 (2003).
pubmed: 12928424
Wang, H. Q. & Smart, R. C. Overexpression of protein kinase C-α in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-α expression but not tumor promotion. J. Cell Sci. 112, 3497–3506 (1999).
pubmed: 10504298
Hara, T. et al. Deficiency of protein kinase Cα in mice results in impairment of epidermal hyperplasia and enhancement of tumor formation in two-stage skin carcinogenesis. Cancer Res. 65, 7356–7362 (2005).
pubmed: 16103087
Reddig, P. J. et al. Transgenic mice overexpressing protein kinase Cδ in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 59, 5710–5718 (1999).
pubmed: 10582689
Aziz, M. H., Wheeler, D. L., Bhamb, B. & Verma, A. K. Protein kinase Cδ overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2. Cancer Res. 66, 713–722 (2006).
pubmed: 16424000
Miyamoto, A. et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 416, 865–869 (2002). This paper presents a description of B cell lymphoproliferative disorder in the PKCδ knockout mouse.
pubmed: 11976687
Mecklenbrauker, I., Saijo, K., Zheng, N. Y., Leitges, M. & Tarakhovsky, A. Protein kinase Cδ controls self-antigen-induced B-cell tolerance. Nature 416, 860–865 (2002).
pubmed: 11976686
Kuehn, H. S. et al. Loss-of-function of the protein kinase Cδ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. Blood 121, 3117–3125 (2013).
pubmed: 23430113
pmcid: 3630827
Allen-Petersen, B. L., Carter, C. J., Ohm, A. M. & Reyland, M. E. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene 33, 1306–1315 (2014).
pubmed: 23474764
Symonds, J. M. et al. Protein kinase Cδ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 71, 2087–2097 (2011).
pubmed: 21335545
pmcid: 3271733
Leitges, M. et al. Immunodeficiency in protein kinase Cβ-deficient mice. Science 273, 788–791 (1996).
pubmed: 8670417
Tsui, C. et al. Protein kinase C-β dictates B cell fate by regulating mitochondrial remodeling, metabolic reprogramming, and heme biosynthesis. Immunity 48, 1144–1159.e5 (2018).
pubmed: 29884460
pmcid: 6015119
Pfeifhofer, C. et al. Defective IgG2a/2b class switching in PKCα
pubmed: 16670309
Martini, S. et al. PKCε promotes human T
pubmed: 29280140
Castrillo, A. et al. Protein kinase Cε is required for macrophage activation and defense against bacterial infection. J. Exp. Med. 194, 1231–1242 (2001).
pubmed: 11696589
pmcid: 2195971
Pfeifhofer, C. et al. Protein kinase Cθ affects Ca
pubmed: 12782715
pmcid: 2193906
Thuille, N. et al. Loss-of-function phenotype of a PKCθ
pubmed: 31694643
pmcid: 6836476
He, X. et al. Targeting PKC in human T cells using sotrastaurin (AEB071) preserves regulatory T cells and prevents IL-17 production. J. Invest. Dermatol. 134, 975–983 (2014).
pubmed: 24192715
Kwon, M. J., Ma, J., Ding, Y., Wang, R. & Sun, Z. Protein kinase C-θ promotes T
pubmed: 22586032
pmcid: 3484892
Kong, K. F. et al. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat. Immunol. 15, 465–472 (2014).
pubmed: 24705298
pmcid: 4040250
Chida, K. et al. Disruption of protein kinase Cη results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res. 63, 2404–2408 (2003).
pubmed: 12750259
Park, D. W. et al. TLR2 stimulates ABCA1 expression via PKC-η and PLD2 pathway. Biochem. Biophys. Res. Commun. 430, 933–937 (2013).
pubmed: 23261454
Fu, G. et al. Protein kinase Cη is required for T cell activation and homeostatic proliferation. Sci. Signal. 4, ra84 (2011).
pubmed: 22155788
pmcid: 3242502
Wallace, J. A. et al. Protein kinase Cβ in the tumor microenvironment promotes mammary tumorigenesis. Front. Oncol. 4, 87 (2014).
pubmed: 24795864
pmcid: 4006052
Park, E. et al. Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.aax9340 (2020).
doi: 10.1126/scitranslmed.aax9340
pubmed: 33328330
pmcid: 7116365
Mukai, H. et al. PKN3 is the major regulator of angiogenesis and tumor metastasis in mice. Sci. Rep. 6, 18979 (2016).
pubmed: 26742562
pmcid: 4705536
Hattori, Y., Kikuchi, T., Nakamura, M., Ozaki, K. I. & Onishi, H. Therapeutic effects of protein kinase N3 small interfering RNA and doxorubicin combination therapy on liver and lung metastases. Oncol. Lett. 14, 5157–5166 (2017).
pubmed: 29098022
pmcid: 5652245
Leenders, F. et al. PKN3 is required for malignant prostate cell growth downstream of activated PI3-kinase. EMBO J. 23, 3303–3313 (2004).
pubmed: 15282551
pmcid: 514518
Kraft, A. S., Smith, J. B. & Berkow, R. L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl Acad. Sci. USA 83, 1334–1338 (1986).
pubmed: 3456591
Mackanos, E. A., Pettit, G. R. & Ramsdell, J. S. Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation. J. Biol. Chem. 266, 11205–11212 (1991).
pubmed: 1904062
Szallasi, Z., Smith, C. B., Pettit, G. R. & Blumberg, P. M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem. 269, 2118–2124 (1994).
pubmed: 8294465
Hennings, H. et al. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8, 1343–1346 (1987). This paper demonstrates that despite its shared ability to activate PKC, bryostatin 1 inhibits phorbol ester-promoted tumour formation.
pubmed: 3621472
Boyle, G. M. et al. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PLoS ONE 9, e108887 (2014). This paper presents evidence that the PKC-activating epoxytigliane EBC-46 can trigger tumour regression on intratumoural injection.
pubmed: 25272271
pmcid: 4182759
Miller, J. et al. Dose characterization of the investigational anticancer drug tigilanol tiglate (EBC-46) in the local treatment of canine mast cell tumors. Front. Vet. Sci. 6, 106 (2019).
pubmed: 31111038
pmcid: 6499228
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
pubmed: 12068308
Antal, C. E. et al. Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor. Cell 160, 489–502 (2015).
pubmed: 25619690
pmcid: 4313737
Bangham, C. R. & Ratner, L. How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)? Curr. Opin. Virol. 14, 93–100 (2015).
pubmed: 26414684
pmcid: 4772697
Kataoka, K. et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat. Genet. 47, 1304–1315 (2015). This paper presents a comprehensive description of the mutational landscape of ATLL and the identification of PKCβ as a frequent mutation target.
pubmed: 26437031
Wang, C., Shang, Y., Yu, J. & Zhang, M. Substrate recognition mechanism of atypical protein kinase Cs revealed by the structure of PKCι in complex with a substrate peptide from Par-3. Structure 20, 791–801 (2012).
pubmed: 22579248
Shinohara, H. et al. PKCβ regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J. Exp. Med. 202, 1423–1431 (2005).
pubmed: 16301747
pmcid: 2212994
Soriano, E. V. et al. aPKC inhibition by Par3 CR3 flanking regions controls substrate access and underpins apical-junctional polarization. Dev. Cell 38, 384–398 (2016).
pubmed: 27554858
pmcid: 4998004
Linch, M. Protein Kinase Cι in Mammalian Cell Polarity and Cancer. PhD thesis, Univ. College London (2012).
Shimoyama, M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br. J. Haematol. 79, 428–437 (1991).
pubmed: 1751370
Brat, D. J. et al. Third ventricular chordoid glioma: a distinct clinicopathologic entity. J. Neuropathol. Exp. Neurol. 57, 283–290 (1998).
pubmed: 9600220
Morais, B. A., Menendez, D. F., Medeiros, R. S., Teixeira, M. J. & Lepski, G. A. Chordoid glioma: case report and review of the literature. Int. J. Surg. Case Rep. 7c, 168–171 (2015).
pubmed: 25648470
Rosenberg, S. et al. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Nat. Commun. 9, 2371 (2018).
pubmed: 29915258
pmcid: 6006150
Goode, B. et al. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nat. Commun. 9, 810 (2018). Together with Rosenberg et al. (2018), this paper demonstrates a fully penetrant mutation in PKCα in chordoid gliomas.
pubmed: 29476136
pmcid: 5824822
Madhusudan et al. cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer. Protein Sci. 3, 176–187 (1994).
pubmed: 8003955
pmcid: 2142788
Leitges, M. et al. Knockout of PKCα enhances insulin signaling through PI3K. Mol. Endocrinol. 16, 847–858 (2002).
pubmed: 11923480
Cameron, A. J., Procyk, K. J., Leitges, M. & Parker, P. J. PKCα protein but not kinase activity is critical for glioma cell proliferation and survival. Int. J. Cancer 123, 769–779 (2008).
pubmed: 18508315
Black, A. R. & Black, J. D. Protein kinase C signaling and cell cycle regulation. Front. Immunol. 3, 423 (2012).
pubmed: 23335926
Poli, A., Mongiorgi, S., Cocco, L. & Follo, M. Y. Protein kinase C involvement in cell cycle modulation. Biochem. Soc. Trans. 42, 1471–1476 (2014).
pubmed: 25233434
Gao, Q. et al. PKCα affects cell cycle progression and proliferation in human RPE cells through the downregulation of p27kip1. Mol. Vis. 15, 2683–2695 (2009).
pubmed: 20011080
pmcid: 2791041
Kashiwagi, M. et al. PKCη associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes. Oncogene 19, 6334–6341 (2000).
pubmed: 11175348
Mall, M. et al. Mitotic lamin disassembly is triggered by lipid-mediated signaling. J. Cell Biol. 198, 981–990 (2012).
pubmed: 22986494
pmcid: 3444782
Edens, L. J., Dilsaver, M. R. & Levy, D. L. PKC-mediated phosphorylation of nuclear lamins at a single serine residue regulates interphase nuclear size in Xenopus and mammalian cells. Mol. Biol. Cell 28, 1389–1399 (2017).
pubmed: 28356420
pmcid: 5426852
Goss, V. L. et al. Identification of nuclear βII protein kinase C as a mitotic lamin kinase. J. Biol. Chem. 269, 19074–19080 (1994).
pubmed: 8034666
Larijani, B. et al. Principle of duality in phospholipids: regulators of membrane morphology and dynamics. Biochem. Soc. Trans. 42, 1335–1342 (2014).
pubmed: 25233412
Brownlow, N., Pike, T., Zicha, D., Collinson, L. & Parker, P. J. Mitotic catenation is monitored and resolved by a PKCε-regulated pathway. Nat. Commun. 5, 5685 (2014). This paper defines, for the first time, the cell cycle dependence on PKCε in cells with a dysfunctional Topo2-dependent G2 arrest.
pubmed: 25483024
pmcid: 4272242
Downes, C. S. et al. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372, 467–470 (1994).
pubmed: 7984241
Pandey, N. et al. Topoisomerase II SUMOylation activates a metaphase checkpoint via Haspin and Aurora B kinases. J. Cell Biol. https://doi.org/10.1083/jcb.201807189 (2019).
doi: 10.1083/jcb.201807189
pmcid: 7039214
Deiss, K. et al. A genome-wide RNAi screen identifies the SMC5/6 complex as a non-redundant regulator of a Topo2a-dependent G2 arrest. Nucleic Acids Res. 47, 2906–2921 (2019). This paper demonstrates that a genome-wide screen for genes engaged in the Topo2-dependent G2 arrest provides molecular insight into the context of PKCε dependence.
pubmed: 30590722
Martini, S. et al. PKCε controls mitotic progression by regulating centrosome migration and mitotic spindle assembly. Mol. Cancer Res. 16, 3–15 (2018).
pubmed: 29021232
Kelly, J. R. et al. The Aurora B specificity switch is required to protect from non-disjunction at the metaphase/anaphase transition. Nat. Commun. 11, 1396 (2020).
pubmed: 32170202
pmcid: 7070073
Pike, T., Brownlow, N., Kjaer, S., Carlton, J. & Parker, P. J. PKCε switches Aurora B specificity to exit the abscission checkpoint. Nat. Commun. 7, 13853 (2016).
pubmed: 28004745
pmcid: 5192180
Chen, D., Purohit, A., Halilovic, E., Doxsey, S. J. & Newton, A. C. Centrosomal anchoring of protein kinase C βII by pericentrin controls microtubule organization, spindle function, and cytokinesis. J. Biol. Chem. 279, 4829–4839 (2004).
pubmed: 14594954
Kawamoto, S. & Hidaka, H. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine (H-7) is a selective inhibitor of protein kinase C in rabbit platelets. Biochem. Biophys. Res. Commun. 125, 258–264 (1984).
pubmed: 6239622
Tamaoki, T. et al. Staurosporine, a potent inhibitor of phospholipid/Ca
pubmed: 3457562
Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771–15781 (1991).
pubmed: 1874734
Mackay, H. J. & Twelves, C. J. Targeting the protein kinase C family: are we there yet? Nat. Rev. Cancer 7, 554–562 (2007).
pubmed: 17585335
Roffey, J. et al. Protein kinase C intervention: the state of play. Curr. Opin. Cell Biol. 21, 268–279 (2009).
pubmed: 19233632
Wang, H. B., Wang, X. Y., Liu, L. P., Qin, G. W. & Kang, T. G. Tigliane diterpenoids from the Euphorbiaceae and Thymelaeaceae families. Chem. Rev. 115, 2975–3011 (2015).
pubmed: 25906056
Raghuvanshi, R. & Bharate, S. B. Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: a mini-review. Curr. Top. Med. Chem. 20, 1124–1135 (2020).
pubmed: 32209043
Saavedra, A. et al. Chelerythrine promotes Ca
pubmed: 28130160
Dar, M. I. et al. Rottlerin is a pan phosphodiesterase inhibitor and can induce neurodifferentiation in IMR-32 human neuroblastoma cells. Eur. J. Pharmacol. 857, 172448 (2019).
pubmed: 31202802
Meyer, T. et al. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer 43, 851–856 (1989).
pubmed: 2714889
Kayser, S., Levis, M. J. & Schlenk, R. F. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Expert. Rev. Clin. Pharmacol. 10, 1177–1189 (2017).
pubmed: 28960095
Graves, P. R. et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600–5605 (2000).
pubmed: 10681541
Bourhill, T., Narendran, A. & Johnston, R. N. Enzastaurin: a lesson in drug development. Crit. Rev. Oncol. Hematol. 112, 72–79 (2017).
pubmed: 28325267
Carducci, M. A. et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cβ inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24, 4092–4099 (2006).
pubmed: 16943527
Clamp, A. & Jayson, G. C. The clinical development of the bryostatins. Anticancer Drugs 13, 673–683 (2002).
pubmed: 12187323
Ku, G. Y. et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother. Pharmacol. 62, 875–880 (2008).
pubmed: 18270704
Panizza, B. J. et al. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine 50, 433–441 (2019).
pubmed: 31810818
pmcid: 6921293
Decatur, C. L. et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 134, 728–733 (2016).
pubmed: 27123562
pmcid: 4966162
Gresset, A., Sondek, J. & Harden, T. K. The phospholipase C isozymes and their regulation. Subcell. Biochem. 58, 61–94 (2012).
pubmed: 22403074
pmcid: 3638883
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02273219?term=aeb071&draw=2&rank=1 (2018).
Skvara, H. et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J. Clin. Invest. 118, 3151–3159 (2008).
pubmed: 18688284
pmcid: 2496962
Piperno-Neumann, S. et al. Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071. Mol. Cancer Ther. https://doi.org/10.1158/1535-7163.Mct-19-0098 (2020).
doi: 10.1158/1535-7163.Mct-19-0098
pubmed: 32029634
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03947385 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02601378 (2020).
Kapiteijn, E. et al. Abstract CT068: a phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma. Cancer Res. 79, CT068–CT068 (2019).
Robertson, M. J. et al. Phase II study of enzastaurin, a protein kinase Cβ inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 1741–1746 (2007).
pubmed: 17389337
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03263026 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03492125 (2019).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01737502 (2020).
Erdogan, E. et al. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Cι. J. Biol. Chem. 281, 28450–28459 (2006).
pubmed: 16861740
Suzuki, A. & Ohno, S. The PAR–aPKC system: lessons in polarity. J. Cell Sci. 119, 979–987 (2006).
pubmed: 16525119
Drummond, M. L. & Prehoda, K. E. Molecular control of atypical protein kinase C: tipping the balance between self-renewal and differentiation. J. Mol. Biol. 428, 1455–1464 (2016).
pubmed: 26992354
pmcid: 4848065
Etienne-Manneville, S. From signaling pathways to microtubule dynamics: the key players. Curr. Opin. Cell Biol. 22, 104–111 (2010).
pubmed: 20031384
Murray, N. R. & Fields, A. P. Atypical protein kinase Cι protects human leukemia cells against drug-induced apoptosis. J. Biol. Chem. 272, 27521–27524 (1997).
pubmed: 9346882
Weichert, W., Gekeler, V., Denkert, C., Dietel, M. & Hauptmann, S. Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int. J. Oncol. 23, 633–639 (2003).
pubmed: 12888898
Zhang, L. et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCι as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res. 66, 4627–4635 (2006).
pubmed: 16651413
Eder, A. M. et al. Atypical PKCι contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 12519–12524 (2005).
pubmed: 16116079
Regala, R. P. et al. Atypical protein kinase Cι is an oncogene in human non-small cell lung cancer. Cancer Res. 65, 8905–8911 (2005).
pubmed: 16204062
Li, Q. et al. Correlation of aPKC-ι and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Hepatob. Pancreat. Dis. Int. 7, 70–75 (2008).
Yang, Y. L. et al. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 47, 127–136 (2008).
pubmed: 17990328
Scotti, M. L., Bamlet, W. R., Smyrk, T. C., Fields, A. P. & Murray, N. R. Protein kinase Cι is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res. 70, 2064–2074 (2010).
pubmed: 20179210
pmcid: 2881466
Ishiguro, H. et al. aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc. Natl Acad. Sci. USA 106, 16369–16374 (2009).
pubmed: 19805306
Ma, L. et al. Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis. Cell 152, 599–611 (2013).
pubmed: 23374352
pmcid: 3963830
Reina-Campos, M., Diaz-Meco, M. T. & Moscat, J. The dual roles of the atypical protein kinase Cs in cancer. Cancer Cell 36, 218–235 (2019). This paper presents a detailed commentary on aPKC in cancer models.
pubmed: 31474570
pmcid: 6751000
Reina-Campos, M. et al. Increased serine and one-carbon pathway metabolism by PKCλ/ι deficiency promotes neuroendocrine prostate cancer. Cancer Cell 35, 385–400.e9 (2019).
pubmed: 30827887
pmcid: 6424636
Nakanishi, Y. et al. Simultaneous loss of both atypical protein kinase C genes in the intestinal epithelium drives serrated intestinal cancer by impairing immunosurveillance. Immunity 49, 1132–1147.e7 (2018).
pubmed: 30552022
pmcid: 6301096
Huang, X. et al. An atypical protein kinase C (PKCζ) plays a critical role in lipopolysaccharide-activated NF-κB in human peripheral blood monocytes and macrophages. J. Immunol. 182, 5810–5815 (2009).
pubmed: 19380829
Murray, N. R. et al. Protein kinase Cι is required for Ras transformation and colon carcinogenesis in vivo. J. Cell Biol. 164, 797–802 (2004).
pubmed: 15024028
pmcid: 2172278
Regala, R. P. et al. Atypical protein kinase Cι is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res. 69, 7603–7611 (2009). This paper demonstrates that knockout of PKCι suppresses lung tumour formation at switch on of G12D-mutant K-Ras expression.
pubmed: 19738040
pmcid: 2756303